
Citing FDA’s slow guidance, the American Pharmacists Association is requesting delay in November 2023 DSCSA enforcement.
Citing FDA’s slow guidance, the American Pharmacists Association is requesting delay in November 2023 DSCSA enforcement.
How taking steps to incorporate data into all regulatory and labeling operations helps firms avoid retroactively planning to recapture information
While this concern is causing ripples in the global supply chain, technological and regulatory advances can help address the issue
Wholesalers continue to worry about manufacturer commitment to timely compliance
Following a decade of solid groundwork to modernize regulatory information management in life sciences, leading companies have now shifted their focus to how they might exploit this new digital landscape
Allows CDMO’s regulatory, consulting services to further expand into the pharma market
Law firm to feature life sciences practice in New Jersey and Philadelphia
Innovation in pharma manufacturing as paradigms shift and biotech and personalized therapies move through clinical trials at pace
Location expands company’s pharmacovigilance, regulatory affairs services
Partnership adds technological offerings to PharmaLex’s repertoire
As a result of the United States Supreme Court’s overturning of Roe v. Wade and Planned Parenthood v. Casey, pharmacy providers are looking to state laws and other recently issued federal guidance in determining how they can compliantly meet patient needs and deliver medications.
Pharmaceutical distribution today is anything but monolithic. While companies in this space are grappling with issues ranging from inflation and supply chain disruption to workforce scarcity and DSCSA implementation, there’s still plenty of room for smaller players to stake out part of the terrain to call their own
Faster approvals, more accurate and timely medicines monitoring—all enabled by harmonized, consistent and reliable data—will drive improved patient outcomes.
The EPCIS communications standard is “recommended,” and trading partners are identified
The Health System Owned Specialty Pharmacy (HOSP) Alliance‘s Melissa Goff responds to the news of the FTC investigation into PBM practices news and outlines the alliance‘s vision for the integrated specialty pharmacy industry
Features an ATP solution to allow for efficiency
IQVIA’s Jens-Olaf Vanggaard discusses the challenges of managing regulatory intelligence on a global scale.
The clock is ticking on a massive effort to bring interoperable, electronic tracking of pharma shipments in the US
A recommended checklist for manufacturers as they enlist distributor and 3PL support—and the important questions they should be asking themselves
Pressure is mounting ahead of looming unit-level serialization required by the Drug Supply Chain Security Act—necessitating a wide scope of collaboration on compliance
Outlining the work of the Open Credentialing Initiative in establishing digital proof of identity, licensure status, and authorship using digital wallets and verifiable credentials
After years of preparation, the European Union will be the first to adopt the Identification of Medicinal Products (IDMP) standards in 2023. Robin Schilling identifies three critical steps life sciences organizations can take toward a full-proof strategy that supports the changing regulatory requirements
For pharma companies, an investment in a digital risk management tool is worth considering if they want to meet the European Union's regulatory requirements for pharmaceutical transport and wholesalers
FDA’s Unapproved Drug Initiative (UDI) is a well-intentioned program in its encouragement of formal FDA review for unapproved legacy medications. But it has inadvertently created financial challenges and access issues, write Steven Lucio and Jenna Stern
From November 2023, the Drug Supply Chain Security Act requires healthcare manufacturers, distributors, providers, and dispensers to exchange the serialized item-level product information that has been collected, standardized, and digitized. Hitting this deadline hinges on intensive collaboration between manufacturers and their supply chain partners that must begin now